Newsroom

CHARLOTTE, N.C.--(BUSINESS WIRE)--Barings BDC, Inc. (NYSE: BBDC) (“Barings BDC” or the “Company”) today announced the early termination of its existing credit support agreement (“original CSA”) associated with the Company’s acquisition of Sierra Income Corporation (“Sierra”), and the implementation of a new credit support agreement covering the remaining investments in two Sierra legacy portfolio companies. The original CSA, entered into on February 25, 2022 in connection with the Sierra merger...

DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the launch of its PrEP Wisdom campaign, designed to empower people to make informed decisions about long-acting injectable (LAI) HIV prevention, beyond the dosing schedules. The campaign features TV personality Michelle Visage, a long-time HIV and LGBTQ advocate. Approximately 2.2 million people in the US could benefit from pre-exposure prophyl...

NEW YORK--(BUSINESS WIRE)--Tradewinds Universal (OTC: TRWD), a holdings company executing a consolidation strategy in the experiential hospitality sector, today announced the relocation of its corporate headquarters to Las Vegas, Nevada, effective June 1, 2026. Effective June 1, 2026, TRWD’s principal corporate offices will be located at 1531 S Las Vegas Blvd, Las Vegas, NV 89104, the headquarters of Peppermint Hippo. The relocation reflects the deepening relationship between Tradewinds Univers...

NEW HAVEN, Conn. & SAN DIEGO, Calif.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Avenzo through a merger transaction (the "Merger"). Upon completion of the Merger, the combined company is expected to operate under the name Avenzo Therapeutic...

LEAWOOD, Kan.--(BUSINESS WIRE)--AMC Entertainment (NYSE: AMC), the largest theatrical exhibitor in the United States and the world, welcomed more than 4.2 million moviegoers to its U.S. AMC Theatres and internationally at its ODEON Cinemas this past weekend, from Thursday through Sunday. After yet another strong weekend at the box office in May, both domestically and globally AMC Entertainment received 25.5 million guests at our theatres, recording the highest-attended month of May since 2019....

DENVER & LONDON--(BUSINESS WIRE)--TaoWeave, Inc. (Nasdaq: TWAV) today announced its entry into the emerging Physical AI market through an investment in Manako Labs Ltd. and a preferred North American commercialization partnership. The transaction marks TaoWeave’s first operating investment in artificial intelligence and expands TaoWeave’s strategy beyond digital asset treasury activities into enterprise AI deployment, commercialization, and recurring operating revenue. Under the agreements, Tao...

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP and Motley Rice LLC regarding the Shoals Technologies Securities Litigation: UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION In re SHOALS TECHNOLOGIES GROUP, INC. SECURITIES LITIGATION Civil Action No. 3:24-cv-00334   Judge Waverly D. Crenshaw, Jr.   Magistrate Judge Barbara D. Holmes                 This Document Relates To: CLASS ACTION ALL ACTIONS   DEMAND...

OSHKOSH, Wis.--(BUSINESS WIRE)--Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, announced today it has received two delivery orders from the U.S. Marine Corps for the Remotely Operated Ground Unit for Expeditionary Fires (ROGUE-Fires) Block 2 Production, totaling $92M. Built on the battle-tested Oshkosh Defense Joint Light Tactical Vehicle (JLTV), ROGUE-Fires combines next-generation autonomy with the protection, mobility, speed, and off-road capability Marines rely on in aust...

CHICAGO--(BUSINESS WIRE)--Blood test shows potential for noninvasive monitoring of tumor microenvironment changes and emerging treatment resistance in sarcoma....

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. Patients in the investigational arms were tr...